Navigation Links
PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
Date:9/6/2012

INCLINE VILLAGE, Nev., Sept. 6, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the third quarter ending September 30, 2012, of approximately $85 million, as compared with actual royalty revenue of $83 million for the third quarter of 2011, a two percent increase. 

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

The forecasted growth in royalty revenues is driven by increased second quarter 2012 sales of Herceptin®, Lucentis® and Xolair® for which PDL receives royalties in the third quarter of 2012. Third quarter revenues will include royalties on second quarter sales of Perjeta®, which was approved in the U.S. on June 8, 2012.  Sales of Avastin®, Herceptin, Lucentis, Xolair and Perjeta (the Genentech Products) are subject to a tiered royalty rate for product that is made or sold in the United States and a flat royalty rate of three percent for product that is manufactured and sold outside of the United States (ex-US manufactured and sold).  The net sales thresholds and the applicable royalty rates for the Genentech Products are outlined below:   Genentech Products Made or Sold in US

Royalty RateNet sales up to $1.5 billion

3.0%Net sales between $1.5 billion and $2.5 billion

2.5%Net sales between $2.5 billion and $4.0 billion

2.0%Net sales exceeding $4.0 billion

1.0%Genentech Products Made and Sold ex-USNet sales

3.0%The third quarter royalty payment received from Genentech included royalties based on worldwide sales.

Revenue guidance for the third quarter of 2012 is net of an estimated payment due under our February 2011 settlement agreement with Novartis AG (Novartis
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
3. CeNeRx BioPharma Completes $4.85 Million Financing
4. PDL BioPharma Completes Regular Quarterly Dividend Payment
5. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
6. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
7. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
8. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
9. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
10. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
11. Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... MARINO, Calif. , May 23, 2013 /PRNewswire/ ... today a strategic alliance with DAK Renewable Research ... the corn oil yield. VG Energy is a ... (OTC Pink: VGLS). VG Energy,s exclusively ... to increase the oil yield in plants, possessing ...
(Date:5/23/2013)... EXTON, Pa. , May 23, 2013 /PRNewswire/ ... leading research and advisory firms for specialized biopharmaceutical ... gastroenterologists, hepatologists, and infectious disease specialists reported that ... warehousing patients (e.g., intentionally delaying treatment) in anticipation ... physicians than six months ago, when only 6 ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013  Verenium ... biotechnology company focused on the development and commercialization of ... , Chief Financial Officer, will present at two ... Mr. Black will present at the Second Annual ... at the Grand Hyatt Hotel in New York City.  ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
... First in Europe To Treat Patients With New ... Focused Radiation Therapy, ... first European patient has been treated in the company,s,pivotal global clinical ... of age-related macular degeneration (AMD). Wet AMD,is the most progressive form ...
... Nektar,Therapeutics (Nasdaq: NKTR ) announced today that it ... Focus on Healthcare Conference in New,York at the Millennium ... ET., The presentation and Q&A session will be ... on the Investor Relations, Events,Calendar section of the Nektar ...
... Technologies, Inc.,a developer of NanoReactor droplet-based microfluidic ... as President and Chief,Executive Officer. McNary will ... driving RainDance Technologies, vision and the upcoming,commercial ... the Life,Sciences and other related markets., ...
Cached Biology Technology:First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD 2First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD 3RainDance Technologies Appoints McNary President and CEO 2RainDance Technologies Appoints McNary President and CEO 3
(Date:5/23/2013)... (May 23, 2013) A new report from ... for helping pupils engage in at least 60 minutes ... day. , No more than half of American youth ... of vigorous or moderate intensity physical activity daily, according ... "Because children are in school for nearly half of ...
(Date:5/23/2013)... Wis. In an age when microbial pathogens are ... tamp down infection, a team of Wisconsin scientists has ... curbing the bacteria that cause staph infections. , Writing ... Society , a group led by University of Wisconsin-Madison ... with the "quorum sensing" behavior of Staphylococcus aureus ...
(Date:5/22/2013)... major new effort to educate the public and decision ... clean water that looms ahead in the 21st century. ... current edition of Chemical & Engineering News , ... the world,s largest scientific society. , Bassam Z. Shakhashiri, ... Ph.D., explain that shortages of reliable supplies of fresh ...
Breaking Biology News(10 mins):Schools should provide students with daily physical activity, IOM recommends 2University of Wisconsin chemists find new compounds to curb staph infection 2
... cells in a growing embryo must chart their course to distant ... yet to surface. In a study published in the current issue ... Studies have recovered a key signal that guides motor neurons ... find their way down the length of limbs such as arms, ...
... oblivious to the odor in the locker room after a ... of sweat. Research by Prof. Doron Lancet and research student ... in PLoS Biology, has now shown that this difference is ... takes a back seat to our other senses, but humans ...
... ... Informed and In Touch, WALL, N.J., Nov. 20 ... biometric,identification and wireless public safety, was featured in a recent,televised report ... the ABC affiliate in Oklahoma City. The,November 18th report highlighted the ...
Cached Biology News:Salk scientists identify key nerve navigation pathway 2Salk scientists identify key nerve navigation pathway 3BIO-key(R) PocketCop(R) Project 'Leading the Nation' According to Televised Report 2
... The Helios gene gun low-pressure system, 220-240 ... biomaterials into cells. This handheld device employs an ... other biomaterial-coated gold microcarriers from the inner wall ... cells. This system can be used for in ...
... Hybridization Wash Pack provides optimized blocking ... Preparation Quality Clarifier: Ready-to-use wash solutions ... SigmaScreen(tm) APS Coated Slides for Microarrays ... Hybridization Blocking Buffer: 1L • Microarray ...
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Biology Products: